@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAjIu6VZut0P_g9X3i_SwZMCGvuPXMRySel7a8Wgc778k> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAjIu6VZut0P_g9X3i_SwZMCGvuPXMRySel7a8Wgc778k#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix proteinModification: <http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00000> .
@prefix psimod: <http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:> .
@prefix do: <http://disease-ontology.org/term/DOID:> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: hgnc:3676;
    a Protein: .
  
  sub:_2 belv:variantOf hgnc:3690;
    a proteinModification:, psimod:00696 .
  
  sub:_3 occursIn: do:9538, species:9606;
    rdf:object sub:_2;
    rdf:predicate belv:increases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "p(HGNC:FGF2) -> p(HGNC:FGFR3,pmod(P,Y))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_5;
    pav:version "20131211" .
  
  sub:_4 prov:value "Figure 5. This is a figure in the review representing the cross talk between FGFR3 and IL6 signaling in multiple myeloma cell line KH11; the legend is as follows: Fig. 5. Enhanced proliferation of myeloma cells by interleu- kin- 6 cooperatingwith FGFR3-mediated signals. IL- 6 and FGF induce the distinct intracellular signaling pathways in myeloma cells carryingt(4 ;14)(p16. 3 ;q32) that ectopically express FGFR3. FGF and IL- 6 activate ERK1/ 2, PI- 3 kinase and STAT3, respectively. The serine phosphorylation of STAT3 via the FGF- induced ERK1/ 2 activation contributes to the full activation of STAT3, leadingto the expression of c-myc and bcl- 2 genes and cell proliferation 91 .FRS:FGF receptor substrate.";
    prov:wasQuotedFrom pubmed:17142955 .
  
  sub:_5 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:17142955;
    prov:wasDerivedFrom beldoc:, sub:_4 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:33:07.220+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}